Related Experiment Video
Updated: Aug 11, 2026

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
Challenges facing drug discovery in vascular disease
Phillip Cowley1, Jason Witherington
1Organon Research, Newhouse, Scotland.
Abstract:
The Society for Medicines Research symposium Challenges Facing Drug Discovery in Vascular Disease was held September 30, 2005, at Organon Research, Newhouse, Scotland. The conference brought together an international panel of speakers representing academia and the pharmaceutical industry to review approaches to the treatment of diseases affecting the vasculature. The focus of the meeting was on atherosclerosis and one of its clinical manifestations, stroke. The meeting reviewed current and emerging therapeutic approaches and improving technologies to monitor risk and disease progression in patients.
Related Concept Videos
Drug Discovery: Overview
Pharmacogenomics: Identification of New Drug Targets
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Factors Affecting Drug Distribution: Physiological Barriers
The capillary endothelial barrier allows only smaller molecules below 600 Da (Daltons) to pass through. It also restricts drugs like heparin that are bound to blood components, limiting their movement within the bloodstream.
The...

